You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-NKG2A

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

Not yet recruiting
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer
  • (no location specified)
Oct 30, 2023

SARS-CoV-2 (COVID-19) Infection, Advanced or Metastatic Hematological or Solid Tumor Trial in France (Autophagy inhibitor

Completed
  • SARS-CoV-2 (COVID-19) Infection
  • Advanced or Metastatic Hematological or Solid Tumor
  • Autophagy inhibitor (GNS651)
  • +3 more
  • Lyon, Rhône, France
  • +11 more
Sep 29, 2022

NSCLC Trial in Worldwide (BMS-986315, Nivolumab, Pemetrexed)

Not yet recruiting
  • NSCLC
  • Boise, Idaho
  • +12 more
Oct 17, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 15, 2023

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, China
    Chinese PLA General Hospital
Oct 13, 2022

CRC, Solid Tumor Trial in Beijing (KD-025)

Recruiting
  • CRC
  • Solid Tumor
  • KD-025
  • Beijing, Beijing, China
    Chinese PLA General Hospital
May 16, 2022

Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T

Not yet recruiting
  • Cancer
  • +3 more
  • Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
  • Singapore, Singapore
    National University Hospital
Mar 20, 2022

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Xunyang Changchun Shihua Hospital
Nov 20, 2021

Advanced Solid Tumor Trial in Shanghai (IMC008)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
    Shanghai Changhai Hospital
Apr 19, 2023

Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

Recruiting
  • Advanced Solid Tumors
  • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023

Refractory Metastatic Colorectal Cancer Trial in Guangzhou (CAR-T infusion)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • CAR-T infusion
  • Guangzhou, Guangdong, China
    The Third Affiliated Hospital of Guangzhou Medical University
Feb 9, 2022

Chronic Lymphocytic Leukemia Trial in Columbus (monalizumab)

Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • Columbus, Ohio
    The Ohio State University Wexner Medical Center
Dec 4, 2019

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

Anti-aging Trial in Tours (Anti-aging cosmetic care product)

Completed
  • Anti-aging
  • Anti-aging cosmetic care product
  • Tours, France
    Spincontrol
May 31, 2023

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

NSCLC Trial in Jette (68GaNOTA-Anti-MMR-VHH2)

Recruiting
  • Non-small Cell Lung Cancer
  • Jette, Brussel, Belgium
    Universitair Ziekenhuis Brussel
Jun 27, 2023

NSCLC Trial (Dupilumab, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Dupilumab
  • Cemiplimab
  • (no location specified)
Oct 12, 2023

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Healthy Volunteers Trial in Milano (Berry extract 1, Berry extract 2, Placebo)

Not yet recruiting
  • Healthy Volunteers
  • Berry extract 1
  • +2 more
  • Milano, Italy
    Complife Italia srl
Sep 4, 2023

Primary Sjogren's Syndrome Trial (LY3361237)

Not yet recruiting
  • Primary Sjogren's Syndrome
  • (no location specified)
Mar 20, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Psoriasis Trial in Shanghai, Kunming (Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo)

Active, not recruiting
  • Psoriasis
  • Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
  • Placebo
  • Shanghai, Shanghai, China
  • +2 more
Nov 7, 2022